Global Blood Therapeutics, Inc. (GBT)

NASDAQ: GBT · IEX Real-Time Price · USD
31.79
+0.86 (2.78%)
At close: Jun 24, 2022 4:00 PM
31.95
+0.16 (0.50%)
After-hours: Jun 24, 2022 6:28 PM EDT

Company Description

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD).

The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.

In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development.

It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A.

to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Global Blood Therapeutics, Inc.
Global Blood Therapeutics Logo
Country United States
Founded 2011
Industry Biotechnology
Sector Health Care
Employees 457
CEO Ted Love

Contact Details

Address:
181 Oyster Point Blvd
South San Francisco, California 94080
United States
Phone 650 741 7700
Website globalbloodtx.com

Stock Details

Ticker Symbol GBT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001629137

Key Executives

Name Position
Dr. Ted W. Love M.D. President, Chief Executive Officer and Director
Jeffrey S. Farrow Chief Financial Officer and Principal Accounting Officer
Jung E. Choi Chief Business and Strategy Officer
David L. Johnson Chief Commercial Officer
Dr. Kim Smith-Whitley M.D. Executive Vice President and Head of Research & Development
Dr. David R. Phillips Founder and Advisor
Dr. Matthew P. Jacobson Ph.D. Founder and Advisor
Dr. Andrej Sali Ph.D. Founder and Advisor
Nazila Habibizad Executive Vice President of Operations
Stephanie Yao Senior Director of Corporate Communications and Investor Relations

Latest SEC Filings

Date Type Title
Jun 22, 2022 4 Statement of changes in beneficial ownership of securities
Jun 22, 2022 4 Statement of changes in beneficial ownership of securities
Jun 17, 2022 SC 13G Statement of acquisition of beneficial ownership by individuals
Jun 16, 2022 4 Statement of changes in beneficial ownership of securities
Jun 16, 2022 4 Statement of changes in beneficial ownership of securities
Jun 16, 2022 4 Statement of changes in beneficial ownership of securities
Jun 16, 2022 4 Statement of changes in beneficial ownership of securities
Jun 16, 2022 4 Statement of changes in beneficial ownership of securities
Jun 16, 2022 4 Statement of changes in beneficial ownership of securities
Jun 16, 2022 4 Statement of changes in beneficial ownership of securities